澳大利亚老年人RSV疫苗接种项目减少健康不平等:分布成本效果分析
该研究采用静态多队列马尔可夫模型,模拟澳大利亚≥75岁人群年龄和社会经济状况(SES)特异的RSV疾病进展,比较不接种与两种已批准RSV疫苗(Arexvy和Abrysvo)。分布成本效果分析显示,所有IRSD亚组均从接种中获益,弱势亚组因基线RSV相关住院和死亡概率更高而获得更大健康收益,尽管其接种率相对较低。在假设谈判价格为每剂150澳元、机会成本阈值为每质量调整生命年50000澳元的基准情形下,公平性和净健康获益均增加。
要点
- ≥75岁澳大利亚人接种RSV疫苗可改善总体人群健康并减少健康不平等。
- 弱势亚组健康收益更大,因其基线RSV住院和死亡风险更高。
- 净健康获益对RSV年发病率、症状性RSV概率、疫苗效力和疫苗价格敏感。
核心结论
- 对澳大利亚≥75岁人群接种RSV疫苗可改善总体人群健康并减少现有健康不平等。
- 净健康获益对澳大利亚政府为老年人谈判的潜在疫苗价格敏感。
研究设计与样本
- 采用静态多队列马尔可夫模型模拟≥75岁成人年龄和SES特异的RSV疾病进展。
- 比较不接种与两种已批准RSV疫苗(Arexvy和Abrysvo),SES以IRSD表示。
- 计算净健康获益时考虑疫苗接种项目的机会成本,并用社会福利函数比较健康分布。
主要发现
- 所有IRSD亚组均从接种中获益。
- 弱势亚组尽管接种率相对较低,但因基线RSV相关住院和死亡概率更高而获得更大健康收益。
- 基准情形下(假设谈判价格每剂150澳元、机会成本阈值每QALY 50000澳元),公平性和净健康获益均增加。
关键数值与推荐
- 基准情形假设疫苗谈判价格为每剂150澳元。
- 机会成本阈值为每质量调整生命年50000澳元,适用于所有IRSD亚组。
临床怎么用
- 可为≥75岁人群接种RSV疫苗以改善群体健康并缩小健康不平等。
- 决策需考虑疫苗价格谈判结果及RSV发病率、疫苗效力等关键参数。
局限性
- 净健康获益和公平性影响对RSV年发病率、症状性RSV概率、疫苗效力和疫苗价格敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in individuals aged ≥75 years. Differences in disease burden and vaccine uptake by socio-economic status (SES) are important considerations but are not usually incorporated into traditional cost-effectiveness analyses. We conducted a distributional cost-effectiveness analysis (DCEA) to evaluate RSV vaccination programs for older Australians. METHODS: We utilised a static multi-cohort Markov model to simulate age- and SES-specific RSV disease progression in adults aged ≥75 years, comparing no vaccination with the two currently approved RSV vaccines in Australia (Arexvy and Abrysvo). Where available, we used age and SES stratified healthcare utilisation data for RSV as input in the model, with SES represented by the Index of Relative Socio-economic Disadvantage (IRSD). Net health benefits were calculated considering the opportunity costs associated with the vaccination program. We transformed the health distribution from no vaccination and vaccination scenarios and then compared these using a social welfare function. RESULTS: We found that all IRSD subgroups benefited from vaccination. Disadvantaged subgroups received larger health benefits, despite relatively lower vaccination uptake, due to higher baseline probability of RSV-related hospitalisation and death. Under the base-case assumptions, including an assumed negotiated price of A$150 per vaccine dose and an opportunity cost threshold of A$50,000 per quality-adjusted life year for all IRSD subgroups, we found an increase in equity and an overall increase in net health benefit. The impact of vaccination on net health and on equity was sensitive to annual RSV incidence, probability of symptomatic RSV episode, vaccine efficacies against RSV hospitalisation, and vaccine price. CONCLUSION: RSV vaccination for Australians aged ≥75 years could improve overall population health and reduce existing health inequalities. However, the net health benefits were sensitive to the potential vaccine price to be negotiated by the government in Australia for older adults.
引用
- Paul KK, Torres M, Shih STF, et al. Respiratory syncytial virus (RSV) vaccination program for older Australians reduces health inequalities: a distributional cost-effectiveness analysis. Vaccine. 2026. PMID: 42070372. doi:10.1016/j.vaccine.2026.128644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。